Clinical Trials

The Bladder Cancer Clinical Trials Dashboard is a resource for patients and physicians to find a current listing of open bladder cancer clinical trials. Clinical trials are essential to improving understanding of the disease and make progress against bladder cancer. We want to ensure patients and physicians have the most up-to-date information on bladder cancer clinical trials.

The Dashboard organizes clinical trials by disease state to make it easier to find a trial that is a good match for each patient. In addition, this tool allows you to search specifically for clinical trials in your geographic area. Find the disease state that matches your situation and click on it to see the active clinical trials. If you have questions about a specific clinical trial, click on the trial location and call or email the identified contact person.

The Bladder Cancer Clinical Trials Dashboard is a comprehensive listing of open clinical trials, but may not capture all current trials, especially those that are smaller in scope.  The Dashboard will be updated quarterly, so please contact us at info@bcan.org if you have a bladder cancer trial to include in the listings.

The Dashboard is a collaborative effort of the members of the Clinical Trials Working Group at BCAN’s Bladder Cancer Think Tank. The Bladder Cancer Clinical Trials Dashboard is supported by a generous grant from OncoGenex Pharmaceuticals, Inc.

 

Webinars:
Exploring the Bladder Cancer Clinical Trials Dashboard and Current Studies
Tuesday, December 2, 2014, at 7pm EST
Presented by Dr. Jean Hoffman-Censits, Thomas Jefferson University Hospital
Click here to watch the webinar recording /

 


 
  • Nonmuscle-Invasive Disease
    Treatments for Nonmuscle-Invasive Urothelial Carcinoma
     
  • Urothelial Bladder Cancer
    The most common type of bladder cancer. Urothelial carcinomas are separated clinically into superficial tumors and muscle invasive tumors.
     
  • Immunotherapy
    Use of immune checkpoint inhibitors to target molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
     
  • Muscle Invasive Disease

     
  • Advanced/Metastatic Disease